Shares of Niagen Bioscience (NASDAQ: NAGE) surged 6.39% in after-hours trading following the release of its impressive first-quarter 2025 financial results. The company, which specializes in NAD+ precursor products for healthy aging, reported significant growth across key financial metrics and raised its full-year outlook, sparking investor enthusiasm.

Niagen Bioscience's Q1 performance exceeded expectations, with total net sales climbing 38% year-over-year to $30.5 million. The company's flagship product, Tru Niagen, saw sales increase by 24% to $21.5 million, while Niagen ingredient sales nearly doubled, up 95% to $8.0 million. This robust top-line growth translated into a net income of $5.1 million, or $0.07 per share, marking a substantial improvement from a net loss in the same quarter last year. The company also reported a strong gross margin of 63.4% and Adjusted EBITDA of $4.9 million.

Adding to the positive sentiment, Niagen Bioscience raised its full-year 2025 outlook, projecting net sales growth between 20% and 25%, up from its previous estimate of approximately 18%. This upward revision reflects the company's confidence in the expanding NAD+ market and its strengthened position following recent strategic initiatives, including a corporate rebranding and the expansion of its NAD+ precursor patent portfolio. The combination of strong current performance and an optimistic future outlook appears to be driving the after-hours stock price surge as investors react to the company's growth potential in the healthy aging market.